Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Statin-fibrate combinations are commonly used to treat hyperlipidemia. These drugs have been previously reported to cause rhabdomyolysis with acute renal failure. Whether different statin-fibrate combinations have different risks for rhabdomyolysis is not known. We report a patient who developed rhabdomyolysis with acute renal failure promptly after switching from the combination of pravastatin and fenofibrate to simvastatin and gemfibrozil.
Oldemeyer
J B
JB
Department of Internal Medicine, Creighton University, Omaha, NE, USA.
Lund
R J
RJ
Koch
M
M
Meares
A J
AJ
Dunlay
R
R
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D003327:Coronary Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D011345:Fenofibrate / Q000627:therapeutic use; D015248:Gemfibrozil / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008297:Male; D017035:Pravastatin / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000139:chemically induced*; D019821:Simvastatin / Q000009:adverse effects*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D019821:Simvastatin; D017035:Pravastatin; D015248:Gemfibrozil; D011345:Fenofibrate